Skip to content
DataLookout
Menu

NCT07933289

PlayCuff: a Unilateral Device for Pediatric Upper Limb Rehabilitation

StatusRecruiting
PhaseNot applicable
Primary completion (estimated)
Track this trial

Free. We email you which fields changed when ClinicalTrials.gov updates this record.

Record History

All 1 version: 1 with changes below.

  1. Study First Submitted

Endpoints

Primary

Change in MA2 Range subscale score- intervention
Timeframe: 5 weeks
Number of serious adverse events (SAEs) related or potentially related to the PlayCuff device
Timeframe: 9 weeks

Secondary (16)

Change in MA2 Accuracy, Dexterity, and Fluency subscale scores- intervention
Change in ABILHAND-Kids total score- intervention
Leiter-3 Sustained Attention- intervention
Change in NEPSY-II Inhibition - Intervention
Change in MA2 Range subscale score- baseline
Show 11 moreShow less
Change in MA2 Accuracy, Dexterity, and Fluency subscale scores- baseline
Change in ABILHAND-Kids total score- baseline
Leiter-3 Sustained Attention- baseline
Change in NEPSY-II Inhibition - baseline
System Usability Scale (SUS) score
Evaluation of children's exergame performance based on game scores and successful actions
Change in MA2 Range subscale score- Follow up
Change in MA2 Accuracy, Dexterity, and Fluency subscale scores- follow up
Change in ABILHAND-Kids total score- follow up
Leiter-3 Sustained Attention- follow up
Change in NEPSY-II Inhibition - Follow up

Arms and interventions

PlayCuff InterventionExperimental

This multicenter, exploratory, prospective study will evaluate a 5-week rehabilitation program using the PlayCuff system in children aged 4-8 years with upper-limb motor disability due to congenital or acquired brain injury. The intervention consists of 10 sessions (2/week, 45 minutes each) combining non-immersive virtual reality exergames with task-oriented grasping, manipulation and bimanual activities using concrete materials. Exercises target upper-limb motor control and are adapted to the child's abilities. Participants will be assessed at T-1 (5 weeks before treatment), T0 (before treatment), T1 (after treatment), and T2 (1-month follow-up). The primary outcome is the Melbourne Assessment 2 (MA2). Secondary outcomes include ABILHAND-Kids, the Leiter-3 sustained attention subtest, discrete performance variables recorded during exergames, and the System Usability Scale (SUS). T-1-T0 will assess baseline stability, T0-T1 treatment-related changes, and T1-T2 maintenance of effects.

Devices: Play Cluff Session

Sites

3 sites in 1 country